A Double-blind, Randomized, Placebo Controlled Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment Alone and in Combination with Atorvastatin on Lipoprotein Kinetics

StatusFinished
Effective start/end date1/07/1430/06/17

Funding

  • Amgen Australia Pty Ltd